Inflammatory Bowel Disease News and Research RSS Feed - Inflammatory Bowel Disease News and Research

Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.

There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.
Women with IBD may be at increased risk for developing cervical cancer

Women with IBD may be at increased risk for developing cervical cancer

Women with inflammatory bowel disease (IBD) may be at increased risk of cervical dysplasia and cancer, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office. [More]
Transplanted regulatory T cells may help in controlling inflammatory diseases

Transplanted regulatory T cells may help in controlling inflammatory diseases

With a $2 million grant from the National Institutes of Health, a team of researchers - including Rensselaer Polytechnic Institute professor Juergen Hahn - will investigate the potential of using transplanted regulatory T cells (Tregs) to reduce inflammation in diseases like inflammatory bowel disease, which currently has no known viable treatment options. [More]
Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients’ needs and concerns. [More]
Loyola's Neil Gupta recommends patients to ask four questions when planning a colonoscopy

Loyola's Neil Gupta recommends patients to ask four questions when planning a colonoscopy

"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one." [More]
Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects. [More]
New database on healthy immune system may help design future studies on autoimmune disorders

New database on healthy immune system may help design future studies on autoimmune disorders

An extensive database identifying immune traits, such as how immune cell function is regulated at the genetic level in healthy people, is reported by researchers from the National Institutes of Health (NIH) and their collaborators in the journal Cell. [More]
The Medical Minute highlights risk and symptoms of IBD in children

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD. [More]
Young immigrants to Canada at greater risk of developing IBD

Young immigrants to Canada at greater risk of developing IBD

The younger a person is when they immigrate to Canada, the higher their risk of developing inflammatory bowel disease (IBD), and its major subtypes Crohn's disease and ulcerative colitis, according to a study by researchers at the University of Ottawa, the Institute for Clinical Evaluative Sciences and the Children's Hospital of Eastern Ontario. [More]
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers, which are added to most processed foods to aid texture and extend shelf life, can alter the gut microbiota composition and localization to induce intestinal inflammation that promotes the development of inflammatory bowel disease and metabolic syndrome, new research shows. [More]
Scientists find new links between inflammation and tissue regeneration

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars. [More]
Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis. [More]
Indiana University study reveals connection between mussels and muscles

Indiana University study reveals connection between mussels and muscles

An Indiana University study has revealed that there may be a greater connection between mussels and muscles than previously thought. [More]
Teen girls from rural areas have undiagnosed asthma, face higher risk of depression

Teen girls from rural areas have undiagnosed asthma, face higher risk of depression

Teen girls who live in rural areas are more likely than their male counterparts to have undiagnosed asthma, and they often are at a higher risk of depression, according to researchers at the Medical College of Georgia at Georgia Regents University. [More]
InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference. [More]
Study shows link between autoimmune diseases and gene regulatory elements

Study shows link between autoimmune diseases and gene regulatory elements

Investigators with the National Institutes of Health have discovered the genomic switches of a blood cell key to regulating the human immune system. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
Advertisement